ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

teplizumab

Also written as “Teplizumab”, “teplizumab 1 mg/mL” and “Teplizumab Herold Regimen”.

Its studies are mostly in Diabetes Mellitus, Type 1 · Psoriasis, led by 3 companies.

Drug pageTeplizumab: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Feb 13, 20239 company-led studies, 2 open or runningNext primary completion: Mar 6, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofiits history only52 open or runningphase 4since Feb 13, 2023Mar 13, 2019Mar 6, 2028phase 2 · NCT06791291
MacroGenics30 open or runningphase 3since Oct 7, 2006Oct 7, 2006none ahead
Precigen Actobio T1Dits history only10 open or runningphase 2since Nov 8, 2018Nov 8, 2018none ahead

Also a collaborator on its studies: Eli Lilly.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of MacroGenics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 7, 2006First study: phase 3 study in Diabetes Mellitus, Type 1First studyNCT00385697 · 554 enrolled · United States, Canada, Czechia and more
  2. Jun 12, 2009Phase 3 study in Diabetes Mellitus, Type 1NCT00920582 · 254 enrolled · United States, Belgium, Czechia and more
  3. Aug 4, 2009Phase 2 study in PsoriasisNCT00954915 · 1 enrolled · United States

TargetBeta

CD3E →read by rule
“T-cell surface glycoprotein CD3 epsilon chain other”ChEMBL 37, by rule

Other programs on CD3E

ProgramCompanyFurthest phaseStudies
etentamigAbbViephase 311
obrixtamigBoehringer Ingelheimphase 311
surovatamigAstraZenecaphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
ramantamigJohnson & Johnsonphase 38
cevostamabHoffmann-La Rochephase 38
pasritamigJohnson & Johnsonphase 35
TQB2825Sino Biopharmaceuticalphase 35
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 34
gocatamigMerckphase 34
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492AstraZenecaphase 22

Studies

All 3 MacroGenics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00954915Psoriasis · United States2TerminatedJul 20101
NCT00920582Diabetes Mellitus, Type 1 · United States, Belgium, Czechia and more3TerminatedApr 2012254
NCT00385697Diabetes Mellitus, Type 1 · United States, Canada, Czechia and more3CompletedJun 2010554

How it is read

Names in the registry

  • “Teplizumab”, 4 entries
  • “teplizumab”, 3 entries
  • “teplizumab 1 mg/mL”, 1 entry
  • “Teplizumab Herold Regimen”, 1 entry
  • “Teplizumab 33.3% Herold Regimen”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.